420-P: Effects of Liraglutide on Sudomotor Function in Subjects with Type 2 Diabetes

Background: Sudomotor (SM) dysfunction is present in small-fiber neuropathy and correlates with the presence of cardiac autonomic neuropathy (CAN). In type 2 diabetes (T2DM), CAN is associated with increased risk of cardiovascular (CV) events and treatment with GLP-1 receptor agonists (GLP1RA) has been shown to improve CV outcomes. However, the effects of GLP1RA on autonomic function need further investigation. The aim of this study was to examine the effects of Liraglutide (Lira) on SM function in patients with T2DM. Methods: Randomized, double-blind, placebo (pb) control study of Lira 1.8 mg vs. pb daily for 52 weeks. Primary outcome was mean change in feet and hands electrochemical skin conductance (ESC). Subjects underwent SM function testing (SudoscanTM, Impeto Medical-Paris) and cardiac autonomic function (CAF) testing (ANX 3.0; ANSAR Group, Inc. Philadelphia). Results: We randomized 44 subjects (21 to Lira and 23 to pb). Baseline characteristics were similar between the groups. Main results after 52 weeks of intervention are shown in Table 1. Mean change on feet ESC was not significantly different between the groups (mean=3.37[95%CI=-2.98-9.60] for Liraglutide vs. -1.56 [-5.07-1.95] for placebo, p=0.136). The same was observed for mean hands ESC and CAF. Conclusions: This study did not show changes in SM or CAF function after 52 weeks of treatment with Lira. The small sample size may have contributed to the negative result. Disclosure C. M. Casellini: None. M. D. Bailey: None. H. Parson: None. E. S. Siraj: Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk. Funding Novo Nordisk